191 related articles for article (PubMed ID: 27627783)
21. RECK is not an independent prognostic marker for breast cancer.
Gomes LR; Fujita A; Mott JD; Soares FA; Labriola L; Sogayar MC
BMC Cancer; 2015 Oct; 15():660. PubMed ID: 26449734
[TBL] [Abstract][Full Text] [Related]
22. Interaction with adipocyte stromal cells induces breast cancer malignancy via S100A7 upregulation in breast cancer microenvironment.
Sakurai M; Miki Y; Takagi K; Suzuki T; Ishida T; Ohuchi N; Sasano H
Breast Cancer Res; 2017 Jun; 19(1):70. PubMed ID: 28629450
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
24. CITED2 is expressed in human adrenocortical cells and regulated by basic fibroblast growth factor.
Haase M; Schott M; Bornstein SR; Malendowicz LK; Scherbaum WA; Willenberg HS
J Endocrinol; 2007 Feb; 192(2):459-65. PubMed ID: 17283246
[TBL] [Abstract][Full Text] [Related]
25. Aberrant expression of CITED2 promotes prostate cancer metastasis by activating the nucleolin-AKT pathway.
Shin SH; Lee GY; Lee M; Kang J; Shin HW; Chun YS; Park JW
Nat Commun; 2018 Oct; 9(1):4113. PubMed ID: 30291252
[TBL] [Abstract][Full Text] [Related]
26. Abnormal expression of miR-1 in breast carcinoma as a potent prognostic factor.
Minemura H; Takagi K; Miki Y; Shibahara Y; Nakagawa S; Ebata A; Watanabe M; Ishida T; Sasano H; Suzuki T
Cancer Sci; 2015 Nov; 106(11):1642-50. PubMed ID: 26331797
[TBL] [Abstract][Full Text] [Related]
27. High Ki67/BCL2 index is associated with worse outcome in early stage breast cancer.
Min KW; Kim DH; Do SI; Pyo JS; Chae SW; Sohn JH; Kim K; Lee HJ; Kim DH; Oh S; Choi SH; Park YL; Park CH; Kwon MJ; Moon KM
Postgrad Med J; 2016 Dec; 92(1094):707-714. PubMed ID: 27222586
[TBL] [Abstract][Full Text] [Related]
28. Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases.
Minemura H; Takagi K; Sato A; Yamaguchi M; Hayashi C; Miki Y; Harada-Shoji N; Miyashita M; Sasano H; Suzuki T
Breast Cancer; 2021 Jul; 28(4):915-926. PubMed ID: 33713004
[TBL] [Abstract][Full Text] [Related]
29. NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.
Wan L; Liu T; Hong Z; Pan Y; Sizemore ST; Zhang J; Ma Z
Breast Cancer Res; 2019 Dec; 21(1):148. PubMed ID: 31856858
[TBL] [Abstract][Full Text] [Related]
30. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
[TBL] [Abstract][Full Text] [Related]
31. Both high expression of pyruvate kinase M2 and vascular endothelial growth factor-C predicts poorer prognosis in human breast cancer.
Lin Y; Liu F; Fan Y; Qian X; Lang R; Gu F; Gu J; Fu L
Int J Clin Exp Pathol; 2015; 8(7):8028-37. PubMed ID: 26339369
[TBL] [Abstract][Full Text] [Related]
32. BUB1 immunolocalization in breast carcinoma: its nuclear localization as a potent prognostic factor of the patients.
Takagi K; Miki Y; Shibahara Y; Nakamura Y; Ebata A; Watanabe M; Ishida T; Sasano H; Suzuki T
Horm Cancer; 2013 Apr; 4(2):92-102. PubMed ID: 23288590
[TBL] [Abstract][Full Text] [Related]
33. CITED2 is activated in ulcerative colitis and induces p53-dependent apoptosis in response to butyric acid.
Yoshida T; Sekine T; Aisaki K; Mikami T; Kanno J; Okayasu I
J Gastroenterol; 2011 Mar; 46(3):339-49. PubMed ID: 21165656
[TBL] [Abstract][Full Text] [Related]
34. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.
Yamashita H; Nishio M; Toyama T; Sugiura H; Zhang Z; Kobayashi S; Iwase H
Breast Cancer Res; 2004; 6(1):R24-30. PubMed ID: 14680497
[TBL] [Abstract][Full Text] [Related]
35. Cited2 modulates TGF-beta-mediated upregulation of MMP9.
Chou YT; Wang H; Chen Y; Danielpour D; Yang YC
Oncogene; 2006 Sep; 25(40):5547-60. PubMed ID: 16619037
[TBL] [Abstract][Full Text] [Related]
36. Elevated Aurora B expression contributes to chemoresistance and poor prognosis in breast cancer.
Zhang Y; Jiang C; Li H; Lv F; Li X; Qian X; Fu L; Xu B; Guo X
Int J Clin Exp Pathol; 2015; 8(1):751-7. PubMed ID: 25755770
[TBL] [Abstract][Full Text] [Related]
37. Elevated HMGA2 expression is associated with cancer aggressiveness and predicts poor outcome in breast cancer.
Wu J; Zhang S; Shan J; Hu Z; Liu X; Chen L; Ren X; Yao L; Sheng H; Li L; Ann D; Yen Y; Wang J; Wang X
Cancer Lett; 2016 Jul; 376(2):284-92. PubMed ID: 27063096
[TBL] [Abstract][Full Text] [Related]
38. CITED2 controls the hypoxic signaling by snatching p300 from the two distinct activation domains of HIF-1α.
Yoon H; Lim JH; Cho CH; Huang LE; Park JW
Biochim Biophys Acta; 2011 Dec; 1813(12):2008-16. PubMed ID: 21925214
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
[TBL] [Abstract][Full Text] [Related]
40. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast.
Tsutsui S; Inoue H; Yasuda K; Suzuki K; Higashi H; Era S; Mori M
Oncology; 2005; 68(4-6):398-404. PubMed ID: 16020969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
